Microbiome Sequencing Services Market Size Worth USD 4,654.10 Million by 2034 | CAGR: 10.8%

The global microbiome sequencing services market size is expected to reach USD 4,654.10 million by 2034, according to a new study by Polaris Market Research. The report “Microbiome Sequencing Services Market Size, Share, Trends, Industry Analysis Report: By Technology (Sequencing by Synthesis, Sequencing by Ligation, Sanger Sequencing, and Others), Application, End Use, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Microbiome sequencing services involve the analysis of microbial communities through advanced sequencing technologies, including 16S rRNA gene sequencing, shotgun metagenomics, and metatranscriptomics. These services are widely used to identify and characterize microorganisms in various environments, such as the human gut, skin, soil, and water. By providing insights into microbial diversity and functional roles, microbiome sequencing plays a crucial role in disease research, personalized medicine, drug development, agriculture, and environmental studies.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/microbiome-sequencing-services-market/request-for-sample

The microbiome sequencing services market growth is attributed to increasing research on the role of microbiomes in human health and disease. Key drivers include advancements in next-generation sequencing (NGS) technologies, rising investments from government and private organizations, and growing applications in disease diagnostics and therapeutics. Additionally, the increasing demand for personalized medicine, probiotics, and microbiome-based drug development presents new market opportunities. Emerging microbiome sequencing services market trends such as AI-driven bioinformatics, strategic collaborations, and service expansion in developing regions are further supporting market expansion. As microbiome research continues to gain importance in healthcare, agriculture, and environmental sciences, the demand for sequencing services is expected to grow during the forecast period.

Microbiome Sequencing Services Market Report Highlights

• By technology, the sequencing by synthesis segment holds the largest share of the microbiome sequencing services market revenue due to its high accuracy, cost efficiency, and widespread adoption in next-generation sequencing (NGS) platforms.
• By application, the gastrointestinal disorders segment holds the largest market share in 2024. This prominence is attributed to the critical role of the gut microbiome in maintaining digestive health and its association with various gastrointestinal diseases.
• By region, North America holds the largest share of the global microbiome sequencing services market, primarily due to its well-established healthcare infrastructure and significant research and development activities in genomics and microbiology.
• The Europe microbiome sequencing services market is experiencing significant growth, driven by the increasing prevalence of genetic disorders and a rising preference for self-medication.
• The market features several active key players contributing to its growth and innovation. Notable companies include Baseclear B.V.; Clinical Microbiomics A/S; Mérieux NutriSciences Corporation; Metabiomics Corp.; Microbiome Insights Inc.; Microbiome Therapeutics, LLC; Molzym GmbH & Co. KG; MR DNA; Resphera Biosciences, LLC; Zymo Research Corporation; and others.

Polaris Market Research has segmented the microbiome sequencing services market report on the basis of technology, application, end use, and region:

By Technology Outlook (Revenue – USD Million, 2020–2034)

• Sequencing by Synthesis
• Sequencing by Ligation
• Sanger Sequencing
• Others

By Application Outlook (Revenue – USD Million, 2020–2034)

• Autoimmune Disorder
• Cancer
• Gastrointestinal Disorders
• Others

By End Use Outlook (Revenue – USD Million, 2020–2034)

• Pharmaceutical & Biotechnology Companies
• Academic Research Institutes
• Others

By Regional Outlook (Revenue – USD Million, 2020–2034)

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America